University Hospital of Bordeaux - Department of Dermatology
Bordeaux, 33000, France
Location status: Recruiting
Location contact
Christine ALFARO
CONTACT
Marie BEYLOT-BARRY, MD, PhD
CONTACT
Marie BEYLOT-BARRY, MD, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06476964
A collection of biological samples (skin) will be created to meet the objectives. Skin biopsies will be taken (excluding on face and fold), in accordance with standard practice.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Location status: Recruiting
Christine ALFARO
CONTACT
Marie BEYLOT-BARRY, MD, PhD
CONTACT
Marie BEYLOT-BARRY, MD, PhD
PRINCIPAL_INVESTIGATOR
Skin cancers are the most common type of cancer in human. Among them, cutaneous squamous cell carcinomas (cSCCs) represent the 2nd most frequent, with an incidence that continues to grow (+300% between 1994 and 2006) in line with the ageing of the population and sun exposure habits. cSCCs is a multi-stage carcinogenesis model: the pre-cancerous lesion is actinic keratosis (AK), which can either regress or progressively evolve into cSCC in situ and then infiltrating, and in some patients into a metastatic stage, initially lymph node and then distant, life-threatening. cSCCs are classified as low-risk or high-risk according to clinical and histological criteria associated with the risk of recurrence and metastasis. However, there is currently no tool for predicting this risk for a given cSCC, particularly according to its genetic characteristics. Indeed, the high mutation rate makes it difficult to identify specific genetic profiles. Similarly, there is no tool to predict the potential for a precancerous lesion (AK) to regress or to develop into a cSCC. The aim of this study is to characterize the molecular and metabolic features as well as immunologic landscapes of precancerous AK and cSCCs in order to uncover epithelial and immune cell subpopulations supporting tumor progression.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
Time frame: Day 1
Evaluation of metabolic changes involved in cSCC progression
Time frame: Day 1
Characterization of the immune cells infiltrate Expression of multiple immune cell markers will be assessed in samples from different subtypes of cSCC by single cell RNA sequencing.
Time frame: Day 1
Evaluation of skin differentiation markers
Time frame: Day 1
Evaluation of cSCC aggressiveness markers with the percentage of samples expressing aggressive markers will be assessed by evaluating the proliferation index, degree of differentiation, invasion beyond subcutaneous fat, perineural invasion, vascular invasion level of infiltration following immunohistochemistry analyses on formalin-fixed paraffin-embedded tissue sections.
Time frame: Day 1
Evaluation of cancer proliferative features on skin biopsies with percentage of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) and cell cycle progression (flow cytometer, western).
Contact information is provided by the study sponsor or research team.
Christine ALFARO
CONTACT
Marie BEYLOT-BARRY, MD, PhD
CONTACT
University Hospital, Bordeaux
Other
Acronym: StratiKA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07286318
Actinic Keratosis (AK), Carcinoma
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT03110159
Actinic Keratosis, Keratosis
Phoenix, Arizona, United States
View Trial DetailsNCT03315286
Actinic Keratoses, Behavior
New York, United States
View Trial DetailsNCT00710489
Acne, Acne Vulgaris
Sacramento, California, United States
View Trial Details